Karen L. Wrenn Lectureship: From Diagnostic Tests to Prevention Trials: Advances in Alzheimer's Disease
5:30pm - 6:00pm - Reception
6:00pm - 7:00pm - Lecture
Randall J. Bateman, MD is the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine, director of the Dominantly Inherited Alzheimer Network (DIAN) and director of the DIAN Trials Unit(DIAN-TU).
Bateman's laboratory investigates the causes and methods of diagnosis and treatment of Alzheimer's disease (AD) utilizing a wide variety of assays and techniques. His lab recently reported on a highly accurate blood test for Alzheimer's disease amyloid plaques which can detect AO pathology decades before symptoms of the disease develop. The Bateman lab has focused research projects on tau isoform species in brain, CSF and blood, and also neurofilament biomarkers.
Bateman's research in DIAN has provided evidence for a cascade of events beginning decades before symptom onset that leads to Alzheimer's disease dementia, supporting development of Alzheimer's disease prevention trials. This focus on deep scientific involvement in Alzheimer's disease has led to seminal scientific discoveries, breakthroughs in cerebral spinal fluid (CSF) and blood diagnostic testing and groundbreaking translational studies and therapeutic trials. In 2010, Bateman organized the Autosomal Dominant Alzheimer's Disease Forum, a patient and family advocacy group, and then launched world wide meetings for family members which have grown into annual meetings with family members attending from most continents. The DIAN Expanded Registry is the portal for families with dominantly inherited Alzheimer's disease to become connected to the DIAN studies and other families around the world.
He has collaborated with the FDA, National Institutes of Health (NIH), biotech and pharmaceutical companies. Bateman's many honors include the Scientific American 50 Award recognizing the top SO scientific achievements and the 2019 Potamkin Prize given each year to the leading Alzheimer's research and is a member of the National Academy of Medicine.